

LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synniech@synniech.com
www.synniech.com
October 11, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of Carlo Bertucci and Guy Felix
U.S. Application No. 10/501,067
Filed July 9, 2004

Examiner: N/A
Group Art Unit: 1632

Highly Homogenous Serum Albumin as Chiral Selector

(Attorney Docket No. P27,959 USA)

FILED ELECTRONICALLY ON October 11, 2006

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)**


Sir:

It is requested respectfully that the information identified on the enclosed Form PTO-1449 (Modified) be made of record and considered with respect to the above-referenced patent application. A copy of each non-U.S. patent publication identified on the Form is enclosed. The Examiner is requested to indicate that each item on the enclosed Form PTO-1449 (Modified) has been considered by initialing and dating the enclosed Form and returning a copy of same to the undersigned.

This Supplemental Information Disclosure Statement is filed before a first Office Action on the merits. Identification of information on the attached Form, or in this statement, is not an admission that such information is prior art to the invention claimed in the present application or that such information is in an analogous art area.

The Commissioner is authorized hereby to charge any fees or credit any overpayment associated with this Statement (copy enclosed) to Deposit Account Number 19-5425.

Respectfully submitted,


Jonathan M. Dermott
Registration No. 48,608

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Telephone (215) 923-4466
Facsimile (215) 923-2189

FORM PTO-1449 (MODIFIED)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO. : 10/501,067

FILING DATE: July 9, 2004

FIRST NAMED INVENTOR: C. Bertucci

ART UNIT: 1632

EXAMINER NAME: N/A

ATTORNEY DOCKET NO. P27,959 USA

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	PUBLICATION DATE	NAME
	AA			
	AB			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	PUBLICATION DATE	COUNTRY
	BA			
	BB			

OTHER PUBLICATIONS

	CAA	Hermansson, J.: <i>Chiral HPLC separations of vinca alkaloid analogues on alpha1-acid glycoprotein and human serum albumin columns</i> , J. Chromatogr. 609:163 (1992)
	CBB	Fitos, et al.: <i>Stereoselective allosteric binding interaction on human serum albumin between ibuprofen and lorazepam acetate</i> , Chirality 11,115-120 (1999)
	CCC	Edafiogho, I.O. et al.: <i>Stability study of an anticonvulsant enaminone (E118) using HPLC</i> , J. Lid.Chrom. & Rel. Technol., 24, 565-577 (2001)
	CCD	Abdel-Hamid, M.E., et al.: <i>Stability study of an anticonvulsant enaminone (E118) using HPLC and LC-MS</i> , J. Pharm. Biomed. Anal., 27, 225-234 (2002)
	CCE	Cheng, Y. et al.: <i>Measurements of drug-protein binding by using immobilized human serum albumin liquid chromatography – mass spectrometry</i> , J. Chromatogr. B., 809, 67-73- (2004)
	CCF	Singh, S. and Mehta, J.: <i>"Measurement of drug-protein binding by immobilized human serum albumin-HPLC and comparison with ultrafiltration"</i> , J. Chromatogr. B, 834, 108-116 (2006)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1
October 11, 2006